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Altered regulation of PDK4 expression 
promotes antiestrogen resistance in human 
breast cancer cells
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Abstract 
Acquired or de novo resistance to the selective estrogen receptor modulators tamoxifen and fulvestrant (ICI) is a 
major barrier to successful treatment of breast cancer. Gene expression patterns in tamoxifen resistant (TamR-MCF-7) 
cells were compared to their parental cells (MCF-7L) to identify an aberrantly regulated metabolic pathway. TamR-
MCF-7 cells are cross resistant to ICI and doxorubicin, and have increased mitochondrial DNA. A small subset of genes 
had altered expression in TamR-MCF-7 relative to MCF-7L cells. One of the genes, pyruvate dehydrogenase kinase-4 
(PDK4), phosphorylates pyruvate dehydrogenase (PDH). PDK4 expression was elevated in TamR-MCF-7 cells; this 
result was also observed in a second model of acquired antiestrogen resistance. PDK4 expression is controlled in 
part by glucocorticoid response elements in the PDK4 gene promoter. In MCF-7L cells, PDK4 mRNA expression was 
insensitive to glucocorticoid receptor agonists, while dexamethasone dramatically increased PDK4 expression in 
TamR-MCF-7 cells. Using siRNA to knock down PDK4 expression increased TamR-MCF-7 sensitivity to ICI; in contrast 
adapting cells to growth in glucose depleted media did not affect ICI sensitivity. Despite TamR-MCF-7 cells high levels 
of PDK4 mRNA relative to MCF-7L, TamR-MCF-7 cells have increased PDH activity. Wild type MCF-7 cells are reported 
to be heterozygous for a G to A mutation that results in a substitution of threonine for alanine near PDK4′s catalytic 
site. We found loss of heterozygosity in TamR-MCF-7 cells; TamR-MCF-7 are homozygous for the wild type allele. These 
data support a role for altered regulation of PDH by PDK4 and altered substrate utilization in the development of drug 
resistance in human breast cancer cells.
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Background
Therapies that target the estrogen receptor-α (ER) have 
resulted in significant improvement in clinical outcomes 
for breast cancer patients (Early Breast Cancer Trialists’ 
Collaborative G 2005; Strasser-Weippl et al. 2013). These 
endocrine therapies include selective estrogen recep-
tor modulators (SERMs) such as tamoxifen (Jordan and 
Koerner 1975), molecules that downregulate ER (e.g. ful-
vestrant Wakeling et al. 1991), and aromatase inhibitors 
that reduce expression of the endogenous ER ligand 
estradiol (Wells et  al. 1978; Lipton et  al. 1995). Despite 
these gains, recurrence of breast cancer after endocrine 
therapy is a major barrier to eliminating breast cancer 
mortality (Jordan and O’Malley 2007; Arpino et al. 2009; 
Moy et al. 2015). Mechanisms proposed for the develop-
ment of resistance to ER targeted drugs include altered 
splicing or mutation of ER (Han et  al. 2004; Scott et  al. 
1991; Banerji et  al. 2012), reduced ER expression (Bay-
liss et al. 2007; Chu et al. 2007; Oh et al. 2001), aberrant 
tamoxifen metabolism (Osborne 1993; Osborne et  al. 
1992), altered function of cell cycle proteins regulating 
the G1 to S phase progression (Lehn et al. 2011; Abukh-
deir et al. 2008; Varma et al. 2007; Mukherjee and Conrad 
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2005; Wilcken et  al. 1997), altered interactions of scaf-
fold proteins with downstream signaling proteins (Wallez 
et  al. 2014; Brinkman et  al. 2000), deregulated growth 
factor signaling (Fagan et al. 2012; Brockdorff et al. 2003), 
upregulated NF-kB signaling (Riggins et al. 2005), andro-
gen receptor upregulation (Fujii et  al. 2014), and acti-
vated Myc signaling (Mukherjee and Conrad 2005; Miller 
et al. 2011; Shajahan-Haq et al. 2014). Despite the many 
routes to endocrine therapy resistance in in  vitro mod-
els, the clinical significance is less clear and has not led to 
predictive biomarkers or effective therapies to prevent or 
overcome resistance (Droog et al. 2013).
In the last two decades there has been a resurgence 
of interest in tumor metabolism as an exploitable tar-
get for cancer therapy, and metabolic abnormalities are 
now in the canon of hallmarks of cancer (Hanahan and 
Weinberg 2011; DeBerardinis et  al. 2008). Cancers are 
generally more glycolytic than normal tissue, and this 
was originally interpreted as a compensatory response 
to defects in respiration (Cook and Higuchi 2012). One 
consequence of increased glycolysis is extracellular acidi-
fication, and this has been shown to cause insensitivity to 
endocrine therapies (Yang et  al. 2013). Oncogenes and 
cell cycle regulatory proteins have been shown to regulate 
the metabolism of fuels in addition to cellular prolifera-
tion, with consequences for endocrine therapy in breast 
cancer cells (Shajahan-Haq et  al. 2014; Lee et  al. 2014; 
Wang et al. 2006). Cancer metabolism is diverse, and clin-
ically the mitochondrial DNA (mtDNA) content of breast 
cancer varies with stage, with early and advanced stage 
cancers having higher mtDNA than those diagnosed at 
intermediate stage (Bai et al. 2011). This observation sug-
gests that as cancers progress, they become more reliant 
on mitochondrial function. Consistent with that notion, 
malignant breast cancer cells are metabolically coupled 
with tumor associated fibroblasts, with fibroblasts fer-
menting substrates and providing lactate for oxidation 
by cancer cells; this relationship promotes SERM resist-
ance (Martinez-Outschoorn et al. 2011). Taken together, 
these observations suggest that fuel metabolism is plastic 
in breast cancer cells, and that utilization of fuels impacts 
response to endocrine therapy.
A major determinant of fuel choice is the pyruvate 
dehydrogenase complex (PDH), an enzyme that converts 
pyruvate and coenzyme A to acetylCoA and carbon diox-
ide, reducing one NAD+ to NADH in the process. Dif-
ferent PDH subunits perform the decarboxylation, acyl 
transfer and oxidation/reduction reactions, and each 
subunit has cofactor requirements specific for their 
function. In addition to the abundance of substrate and 
product, PDH activity is also regulated by phosphoryla-
tion and dephosphorylation of the E1 subunit with inac-
tivation of enzymatic activity by phosphorylation. The 
balance of kinase and phosphatase activities determines 
the PDH phosphorylation status. Four isoforms of pyru-
vate dehydrogenase kinase (PDK) are known, each active 
in response to different intracellular and extracellular 
conditions. PDK1 is activated by hypoxia (Mora et  al. 
2003; Kim et  al. 2006); PDK2 is activated by the PDH 
products acetyl CoA and NADH and is inhibited by ADP 
and pyruvate (Hiromasa et  al. 2006); and PDK3 is acti-
vated by ATP (Kato et  al. 2005). Pyruvate dehydroge-
nase kinase-isoform 4 (PDK4), in contrast, is activated 
transcriptionally by hormonal signals such as retinoic 
acid and glucocorticoids, and transcriptionally repressed 
by insulin (Kwon et  al. 2004). Thus while regulation of 
PDK1-3 reflects the immediate energy demands of the 
cell, PDK4 is reflective of whole organism energy balance 
and is upregulated in metabolic conditions such as hiber-
nation (Buck et  al. 2002), sustained exercise (Wang and 
Sahlin 2012; Pilegaard and Neufer 2004), and diabetes 
(Wu et al. 1998).
We previously reported that mitochondrial DNA copy 
number and mitochondrial superoxide were ampli-
fied in LCC9 cells, a cell line sequentially selected from 
parental MCF-7 cells for estrogen independence and 
fulvestrant resistance (Brunner et  al. 1997; Skildum 
et  al. 2011). We reasoned that mitochondrial amplifica-
tion was a response to altered fuel metabolism, and that 
SERM resistant breast cancer cells would have altered 
expression of genes that regulate carbohydrate metabo-
lism. In an independent model of acquired SERM resist-
ance using cells selected directly from parental MCF-7 
for growth in the presence of 4-hydroxytamoxifen (Fagan 
et al. 2012), we used quantitative PCR (qPCR) arrays to 
compare the expression of genes that regulate glucose 
metabolism. PDK4 expression was increased in tamox-
ifen resistant (TamR-MCF-7) cells, and the regulation of 
PDK4 by glucocorticoid receptor ligands was increased 
in TamR-MCF-7 cells. Paradoxically, PDH activity was 
also elevated in TamR cells. We found that parental 
MCF-7L cells were heterozygous for a mutation which 
causes an amino acid substitution near the PDK4 active 
site, and the TamR-MCF-7 cells lost heterozygosity and 
only expressed wild type PDK4. Decreased PDK4 expres-
sion partially restored antiestrogen sensitivity in these 
cells. We conclude that regulatory circuits that control 
oxidation of carbon derived from glucose are altered dur-
ing selection for antiestrogen resistance.
Methods
Cell lines and reagents
The cell lines used are summarized in Table  1. 
ATCC-MCF-7 cells were obtained from the Ameri-
can Type Culture Collection (Soule et  al. 1973). 
MCF-7L and TamR-MCF-7 cells were established as 
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previously described (Fagan et  al. 2012). LCC-MCF-7 
and LCC9 cells were obtained from Dr. Robert Clarke 
of the Georgetown University Lombardi Cancer Center. 
ATCC-MCF-7, LCC-MCF-7 & MCF-7L were routinely 
cultured in phenol red free IMEM with 5 % fetal bovine 
serum (FBS), 1×  penicillin/streptomycin, 6  ng/μL 
bovine pancreatic insulin (Sigma), and 2.5 μg plasmocin 
(Invivogen). TamR-MCF-7 cells were cultured in phenol 
red free IMEM +  5  % charcoal stripped FBS, 1× peni-
cillin/streptomycin, 6 ng/μL insulin, 2.5 μg/L plasmocin 
and 10−7 M 4-hydroxytamoxifen (Sigma). LCC9 cells 
were cultured in phenol red free IMEM + 5 % charcoal 
stripped FBS, 1× penicillin/streptomycin, 6 ng/μL insu-
lin, 2.5 μg/L plasmocin (Invivogen), and 10−9 M fulves-
trant (ICI).
MCF-7-GAL cells were generated by adapting ATCC-
MCF-7 to progressively increased concentrations of 
galactose and decreased concentrations of glucose. Ini-
tially cells were cultured in DMEM (Sigma catalog num-
ber D5030) supplemented with 2 mM glutamine, 1 mM 
pyruvate, 5 % FBS, 1× penicillin/streptomycin, 12.5 mM 
d-glucose and 12.5  mM d-galactose; the concentration 
of glucose in this media is half that in MCF-7′s normal 
media. Over the course of 2 months, cells were allowed 
to grow to confluence, then split into new plates with 
progressively lower concentration of glucose and higher 
concentrations of galactose, until a population of cells 
was derived (MCF-7-GAL) that grew as rapidly in 25 mM 
galactose media as their parental cells grew in 25  mM 
glucose. In the 25  mM galactose media, some glucose 
was provided by FBS, however, the glucose concentration 
in this media was below the detection limit of a glucose 
oxidase based colorimetric assay (data not shown).
d-glucose, d-galactose, dexamethsone, mifepristone, 
4-hydroxytamoxifen, and ICI were purchased from 
Sigma.
Western blots
MCF-7L and TamR-MCF-7 were treated as described, 
and whole cell lysates were prepared in RIPA buffer sup-
plemented with protease inhibitor cocktail, phenylmeth-
anesulfonylfluoride, and sodium fluoride (all purchased 
from Sigma). Lysates were sonicated and cleared by high 
speed centrifugation. Protein concentration in the super-
natants was determined by Bradford assay (BioRad), and 
equal quantities of protein were diluted in 6x-SDS-PAGE 
buffer and boiled. Lysate equivalent to 40 μg protein were 
resolved on 10 % SDS polyacrylamide gel (TGX gels, Bio-
Rad), then transferred to polyvinylidene fluoride mem-
brane. The membrane was blocked with 5 % nonfat dry 
milk in phosphate buffered saline with 1  % Tween-20 
(PBS-T; Tween-20 purchased from Sigma). Membranes 
were incubated overnight at 4 degrees with anti-PDK4 
antibody (Abgent Cat. No. AP7041B) diluted at 1:1000 
in blocking solution. The membrane was washed thrice 
with PBS-T, then incubated for 1 h with horseradish per-
oxidase conjugated secondary antibody diluted 1:1000 in 
blocking solution. The membrane was washed thrice with 
PBS-T, then incubated with enhanced chemilumines-
cence reagents for 2 min (SuperSignal West Pico; Pierce). 
Antibody interactions were visualized by exposing the 
membrane to film. The membrane was then washed with 
PBS-T and, using the procedure described above, probed 
for actin to ensure equal loading (Sigma clone AC-40). 
The images in Fig.  1b were generated by scanning films 
with a flatbed scanner.
Cell cycle assay
MCF-7L and TamR-MCF-7 cells were plated at 106 per 
10 cm dish in MCF-7L’s normal growth media (permis-
sive media for both cell lines). After attaching overnight, 
1 nm ICI or vehicle (DMSO) was added to the cells with-
out changing media. After 48 h, cells were harvested by 
Table 1 Cell lines
The origins of the cell lines used in this study are summarized




Selection for… Source of cells References
MCF-7L University of Minnesota Masonic  
Cancer Center
TamR-MCF-7 MCF-7L Proliferation in the presence of  
4-hydroxytamoxifen in vitro
University of Minnesota Masonic  
Cancer Center
Wallez et al. (2014)
LCC-MCF-7 Georgetown University Lombardi  
Cancer Center
LCC9 LCC-MCF-7 Estrogen independent tumorigenesis 
in vivo; Proliferation in the presence  
of ICI in vitro
Georgetown University Lombardi  
Cancer Center
Pilegaard and Neufer (2004)
ATCC-MCF-7 American Type Culture Collection Brunner et al. (1997)
MCF-7-GAL ATCC-MCF-7 Proliferation in 4.5 mM galactose with 
undetectable glucose
Generated at University of Minnesota 
Medical School, Duluth
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trypsinization and fixed in ethanol. Cells were then cen-
trifuged and the fixative removed by aspiration. The cell 
pellet was resuspended in 0.4 mL fluorescence-activated 
cell sorting buffer (1.37  M NaCl, 27  mM KCl, 43  mM 
Na2HPO4, 14.7  mM KH2PO4, 1  mg/mL ribonuclease 
A, 0.5  mM EDTA, 0.1  % Triton X-100, and 0.2  mg/mL 
propidium iodide), pipetted several times to ensure a 
uniform single-cell suspension, and transferred to a poly-
styrene tube. Cells were incubated at 4 °C in the dark for 
30 min before analysis.
Cells were analyzed on a FACS Caliber flow cytometer, 
and data were collected using CellQuest Pro software 
(Becton–Dickinson). Cells were gated on forward and 
side scatter to eliminate debris and on the width versus 
area of the red fluorescent voltage pulse to eliminate cell 
aggregates. The area of the red fluorescence voltage pulse 
for the gated cells is proportional to their DNA content, 
and the cell cycle profile for each sample was estimated 
using ModFit LT software (Verity Software House). A 
minimum of 10,000 gated cells were analyzed for each 
sample, and triplicate parallel cultures were analyzed for 
each treatment.
siRNA transfection and sulforhodamine B assays
TamR-MCF-7 cells were plated at 10,000 cells per well 
in 24 well plates in MCF-7L cells’ normal growth media. 
After overnight attachment, cells were transfected with 
one of two PDK4 siRNAs (Qiagen Flexitube Hs_PDK4_6 
and Hs_PDK4_7) or a non-specific control siRNA using 
Lipofectamine 2000 (Invitrogen) according to the ven-
dor’s protocol.
To validate efficacy of PDK4 knockdown, cells were 
treated with 1  nM dexamethasone or ethanol vehicle 
1  day after transfection. Two days after treatment, total 
RNA was collected, reverse transcribed to cDNA, and 
used as template for qPCR amplification of PDK4 and 
actin using the methods described above.
One day after transfection cells were treated with 1 and 
5  nM ICI or DMSO vehicle to test the effects of PDK4 
knockdown on antiestrogen sensitivity. Four days later, 
cells were washed with PBS, then fixed in 10 % trichloro-
acetic acid for 30 min at 4 °C. The fixative was removed 
by aspiration and washing gently with tap water; the 
24-well plates were then air dried. Each well was then 
stained with 0.4 % sulforhodamine B (SRB) in 1 % acetic 
acid at room temperature for 30 min, then washed thrice 
in 1  % acetic acid, and air dried. Stained proteins were 
then solubilized in 0.5 mL 10 mM tris base. A 0.1 mL ali-
quot was then transferred to a 96-well microtitre plate. 
SRB absorbance at 565  nm and background absorbance 
at 690 nm were measured spectrophotometrically.
To measure doxorubicin sensitivity, cells were plated 
at 5000 cells per well in 24 well plates and allowed to 
attach overnight. Cells were then treated ±0.02 micro-
molar doxorubicin (Sigma) from freshly prepared stocks 
diluted in water. Cells were cultured for 4 days, and cel-
lular abundance was measured using SRB staining as 
described above.
Quantitative PCR arrays
To compare gene expression patterns in parental MCF-
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Fig. 1 Glucose deprivation results in increased PDK4 protein without a change in mRNA. MCF-7L and TamR-MCF-7 cells were treated for 2 days in 
media containing 4.5 mM glucose or 4.5 mM galactose. a Total RNA was extracted, reverse transcribed, and the products used as template for qPCR 
amplification of PDK4 and b-actin. The average ratio is shown; error bars indicate one standard deviation (n = 3 biological replicates). b Whole cell 
lysates were prepared, and PDK4 and actin protein were visualized by western blotting, first for PDK4 (upper panel), then for actin (lower panel). The 
PDK4 band is indicated by a red arrow; background bands are indicated by black arrows. The actin band is indicated by a blue arrow
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resistance, we employed qPCR arrays containing primer 
sets targeting 81 genes that encode enzymes that control 
different aspects of carbohydrate metabolism (RT2 Pro-
filer PCR Array Human Glucose Metabolism, Qiagen). 
Samples of MCF-7L and TamR-MCF-7 cells were gener-
ated by thawing ampules of each cell line and growing to 
sub-confluence in T75 flasks. Cells were then trypsinized 
and plated at 500,000 cells per 10  cm dish and allowed 
to attach overnight. Cells were then cultured for 2 days. 
Total RNA was isolated from cells using the Qiagen 
RNeasy kit. Using this protocol, four independent sam-
ples from each cell line were prepared on different days 
to account for biological variability in gene expression. 
Three sample sets were used for qPCR arrays, while the 
fourth set was used as a validation set.
RNA quantity and quality were measured using an Agi-
lent Bioanalyzer, a core service provided by the Univer-
sity of Minnesota Genomics Center. The RNA integrity 
number (RIN) scores ranged from 8.60 to 9.10, indicating 
good quality of the RNA preparations. RNA was reverse 
transcribed and genomic DNA eliminated using the RT2 
First Strand kit (Qiagen) according to the manufacturer’s 
instructions, and the products were used as template for 
qPCR arrays. The qPCR array plates were run on a Light 
Cycler 480 thermocycler (Roche), and data were analyzed 
using Microsoft Excel templates supplied by Qiagen.
Pyruvate dehydrogenase activity assays
To measure PDH activity the Pyruvate Dehydrogenase 
Activity Colorimetric Assay Kit from BioVision was used. 
On three consecutive days, identically prepared aliquots 
of cells were thawed from liquid nitrogen and plated on 
T75 tissue culture plates. Cells were grown to sub-con-
fluence, then split into 10  cm tissue culture dishes and 
grown for 2 days.
Assays were conducted on three consecutive days. On 
the day of each assay, cells were harvested by scraping 
cells and counted on a hemocytometer. 1x106 cells were 
Dounce homogenized with 100  μL ice cold PDH assay 
buffer. The samples were kept on ice for 10  min before 
being centrifuged at 10,000×g for 5  min. The superna-
tant was then transferred to a fresh tube. Protein con-
centration in each sample was determined with the 
BioVision BCA Protein Assay Kit II using bovine serum 
albumin standards according to the manufacturer’s pro-
tocols. Equal amounts of protein were added from each 
sample and the reaction volume was adjusted to 50  μL 
with PDH Assay Buffer and transferred to a microtitre 
plate. Triplicate assays were performed on each sam-
ple, and blank reactions were included as negative con-
trols. The plate was immediately measured with the 
plate reader in kinetic mode at 450  nm for 30  min at 
37  °C. Separately, an external NADH standard curve 
was prepared using the BioVision protocol where 0, 2.5, 
5.0, 7.5, 10 and 12.5  nmol/well of NADH standard was 
adjusted to 50 μL/well with PDH assay buffer. 50 μL of 
the reaction mix was added and immediately measured 
with the plate reader in equilibrium mode at 450 nm at 
37 °C. The slopes of the kinetic measurements were used 
to calculate a rate of NADH produced per minute per 
microgram of protein.
mtDNA copy number assay
To measure mitochondrial genome abundance relative 
to the nuclear genome, MCF-7L and TamR-MCF-7 cells 
were plated at 500,000 cells per 10 cm tissue culture dish, 
allowed to attach overnight, washed with PBS, and then 
treated with 10 nM 4-hydroxytamoxifen or ethanol vehi-
cle for 4 days in phenol red free IMEM with 5 % steroid 
hormone depleted serum. Cells were then harvested by 
scraping after exposure to lysis buffer, and total RNase 
treated DNA was isolated using the Qiagen DNeasy kit 
according to the manufacturer’s instructions. 1  μg of 
DNA was used as template for qPCR amplification of 
mitochondrial DNA (a 125 bp portion of the cytochrome 
B coding sequence) and nuclear DNA (a 158 bp intron/
exon boundary spanning fragment of the pyruvate kinase 
gene) as described above.
Statistical analysis
Pairwise comparisons were subjected to Student T-tests 
using Microsoft Excel. Significant differences in experi-
ments with multiple comparisons were evaluated using 
analysis of variance (ANOVA) followed by Tukey–
Kramer Honest Significant Difference tests; this analysis 
was performed using JMP Pro Version 11.
Results
To determine whether cells selected for resistance to the 
SERM 4-hydroxytamoxifen (TamR-MCF-7) had cross 
resistance to the pure antiestrogen fulvestrant (ICI), cell 
cycle phase distribution was compared in TamR-MCF-7 
and parental cells (MCF-7L) after treatment with vehicle 
or 1 nM (ICI) in the presence of 5 % fetal bovine serum. 
Vehicle treated TamR-MCF-7 cells had an increased 
G1 phase population and decreased S phase population 
compared with vehicle treated MCF-7L cells, reflect-
ing a slower rate of proliferation. While MCF-7L cells 
had an increased fraction of cells in the G1 phase and a 
decreased fraction in S phase, TamR-MCF-7 cell cycle 
phase distribution was unaffected by treatment with ICI 
(Fig.  2a), indicating cross resistance to ICI developed 
with selection for 4-hyroxytamoxifen resistance. Because 
resistance to antiestrogen has been associated with resist-
ance to chemotherapy agents (Skildum et  al. 2011), we 
then compared sensitivity to doxorubicin by measuring 
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cell mass after treatment. While 0.02  μM doxorubicin 
resulted in near complete cytotoxicity of MCF-7L cells, 
TamR-MCF-7 cell growth was not affected (Fig. 2b).
To test whether resistance to endocrine and chemo-
therapy may result from or cause a change in metabolic 
capacity, we next compared mitochondrial gene dose 
by quantitative PCR (qPCR) measurement of pyru-
vate kinase, encoded in nuclear DNA, and cytochrome 
B, encoded in mitochondrial DNA (mtDNA) (Fig.  2c). 
We found that TamR-MCF-7 cells had threefold higher 
mtDNA copy number than parental MCF-7L cells. The 
mtDNA copy number was not altered by short term 
treatment with 4-hydroxytamoxifen in either cell line.
The elevated mtDNA copy number of TamR-MCF-7 
cells suggests that a metabolic abnormality may be asso-
ciated with the multi drug resistant phenotype in this 
model. To identify potential mediators of altered metab-
olism, expression of a panel of 81 genes that encode 
enzymes involved in carbohydrate metabolism was 
compared. MCF-7L and TamR-MCF-7 cells were serum 
starved, then treated with 1 nM 17β-estradiol for 1 day. 



































































Fig. 2 Tamoxifen resistant breast cancer cells have elevated mitochondrial DNA and cross resistance to ICI and doxorubicin. a MCF-7L and TamR-
MCF-7 cells were treated for 2 days in 1 nM ICI or vehicle control (DMSO), then harvested and fixed in ethanol. Cell cycle phase distribution was 
determined by flow cytometric measurement of propidium iodide staining per cell. The average percentage of G1, S and G2/M cells are shown; 
error bars indicate one standard deviation (n = 3). b MCF-7L and TamR-MCF-7 cells were treated ±0.02 mm doxorubicin. After 4 days, total cel-
lular mass was measured by sulforhodamine B staining. The average SRB staining is shown; error bars indicate one standard deviation (n = 6). c 
MCF-7L and TamR-MCF-7 cells were treated for 2 days with 10 nm 4-hydroxytamoxifen or control (EtOH). Genomic DNA was extracted and used as 
template for detection of cytochrome B DNA on the mitochondrial genome and pyruvate kinase DNA on the nuclear genome. The average ratio of 
cytochrome B to pyruvate kinase is shown; error bars indicate one standard deviation (n = 3)
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which was used as template in pathway targeted qPCR 
arrays. The expression of three genes exceeded a two-
fold difference with statistical significance (p  <  0.05) in 
TamR-MCF-7 cells: Glucokinase was expressed at lower 
levels in TamR-MCF-7, while phosphoglucomutase and 
PDK4 were expressed at higher levels in TamR-MCF-7 
cells (Additional file 1: Figure S1). PDK4 encodes a regu-
latory kinase that phosphorylates and inhibits pyruvate 
dehydrogenase (PDH), a major determinant of substrate 
utilization in cells, and is the subject of the current study; 
the significance of glucokinase and phosphoglucomutase 
expression in this model will be explored separately.
To confirm the expression difference in PDK4, prim-
ers were designed to amplify an exon boundary spanning 
fragment of its cDNA (Table 2). PDK4 was measured in 
cDNA from cells treated identically to those used in the 
qPCR arrays (the ‘validation set’) using qPCR; 18 s rRNA 
was used to confirm equal loading. While the pathway 
targeted qPCR arrays revealed a two fold relative differ-
ence in PDK4, using single gene qPCR with quantitation 
based on a five point standard curve, we found that PDK4 
mRNA was five times more abundant in TamR-MCF-7 
relative to their parental cells, with no difference in 18s 
rRNA (Fig. 3a).
The PDK4 promoter contains multiple glucocorticoid 
response elements. To test whether PDK4 expression was 
dependent on glucocorticoid receptor (GR) activity, we 
treated MCF-7L and TamR-MCF-7 with the GR agonist 
dexamethasone and the antagonist mifepristone in serum 
free media. To account for biological variability, triplicate 
cultures were prepared. In the cells treated with vehicle 
control (EtOH), we found elevated expression of PDK4 
in TamR-MCF-7 cells (Fig.  3b), confirming our previ-
ous observations. While the GR ligands had no effect on 
PDK4 expression in MCF-7L cells, dexamethasone treat-
ment resulted in an approximately five fold increase in 
PDK4 mRNA in TamR-MCF-7 cells. Mifepristone treat-
ment alone caused a decrease in PDK4 expression in 
TamR-MCF-7 cells, but the change was not statistically 
significant.
To test whether increased PDK4 mRNA expression is a 
general phenomenon or is specific to the TamR-MCF-7 
model of acquired antiestrogen resistance, we tested the 
dexamethasone induction of PDK4 mRNA in an inde-
pendent model. In contrast to TamR-MCF-7 cells direct 
selection for growth in the presence of 4-hydroxytamox-
ien in vitro, LCC9 cells were selected from MCF-7 cells 
first for estrogen independence in ovariectomized nude 
mice, then selected for ICI resistance in  vitro (Brunner 
et al. 1997). Relative to their parental LCC-MCF-7 cells, 
LCC9 cells exhibited higher basal PDK4 mRNA expres-
sion; dexamethasone treatment resulted in a ~tenfold 
increase in PDK4 mRNA abundance when treated in 
serum free media (Fig. 3c).
PDK4 is known to inhibit PDH, resulting in decreased 
oxidation of glucose derived carbon in the tricarboxylic 
acid cycle. Physiologically this results in conservation 
of glucose as cells switch to oxidation of fatty acids and 
amino acids. We reasoned that by limiting the ability of 
cells to gain ATP through glycolysis by substituting galac-
tose for glucose (Frey 1996), we could increase expression 
of PDK4 and test whether increased PDK4 expression 
resulted in altered sensitivity to SERMs and doxoru-
bicin. MCF-7L and TamR-MCF-7 cells were cultured for 
2 days in media containing fetal bovine serum and either 
4.5 mg/mL glucose or 4.5 mg/mL galactose. PDK4 mRNA 
expression was measured by qPCR, and PDK4 protein 
was measured by western blot. PDK4 mRNA expression 
was not altered by limiting the availability of glucose in 
either cell line (Fig.  1a). In contrast to the consistently 
elevated PDK4 mRNA observed in TamR-MCF-7, we 
found no difference in PDK4 protein detected by West-
ern blot (Fig. 1b); Western blotting was challenging due 
to the consistent presence of non-specific background 
bands (indicated by black arrows in Fig. 1b). PDK4 pro-
tein was increased by culturing cells in galactose in both 
Table 2 Primers
Sequences of primers used to measure expression of human PDK4 mRNA, b-actin mRNA, 18s rRNA, pyruvate kinase from the nuclear genome and cytochrome B from 
the mitochondrial genom are shown along with sequencing primers for PDK4 using genomic DNA and cDNA templates
Primer name Length (BP) Forward primer Reverse primer
18 s rRNA for qPCR 149 5′ TCA ACT TTC GAT GGT AGT CGC CGT 3′ 5′ TCC TTG GAT GTG GTA GCC GTT TCT 3′
β-actin mRNA for qPCR 149 5′ GCC GCC AGC TCA CCA TGG AT 3′ 5′ CAC CAT CAC GCC CTG GTG CC 3′
PDK4 mRNA for qPCR 119 5′ CCT GTG AGA CTC GCC AAC A 3′ 5′ TCC ACC AAA TCC ATC AGG CTC 3′
Cytochrome B genomic for qPCR 125 5′-TGA TAT TTC CTA TTC GCC TAC ACA-3′ 5′-TGT TGT TTG GAT ATA TGG AGG ATG-3′
Pyruvate kinase genomic for qPCR 158 5′-GTC GAT CCA GGA GAA CAT ATC AT-3 5′-CTC CTA GTT TTC ACC CTC ATT TTC-3′
PDK4 genomic for sequencing 367 5′ CAC TGA GAA TGT GAC CCG CT 3′ 5′ AGC CTT GTG TGA AGT AAC CTT AG 3′
PDK4 cDNA for sequencing 393 5′ ATC CTC CCG ACC CAA TTA GT 3′ 5′ ACC CAC TGC TAC CAC ATC ACA 3′
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cell lines, but with a greater magnitude of change in drug 
sensitive MCF-7L cells.
To test the effects of carbohydrate substitution on drug 
sensitivity, ATCC-MCF-7 cells were adapted to growth in 
glucose limited conditions by culturing in progressively 
greater galactose and lower glucose concentrations until a 
population was derived that could grow as well in 4.5 mM 
galactose as parental cells grew in 4.5 mM glucose; these 
cells were designated MCF-7-GAL. To test whether ATP 
generated through glucose fermentation was required for 
sensitivity to antiestrogens, parental and MCF-7-GAL cells 
were treated with 1  nM ICI; treatments were performed 
in both glucose or galactose media. Cell cycle phase dis-
tribution was then determined by DNA staining and flow 
cytometry (Fig.  4a). We found that parental MCF-7 cells 
were sensitive to ICI in both media, showing an increase in 
G1 phase cells and a decrease in S phase cells, though the 
degree of G1 arrest was reduced when treated in galactose. 
MCF-7-GAL cells had a reduced G1 and increased S phase 
fractions in the absence of ICI. MCF-7-GAL cells exhib-
ited a G1 arrest with ICI treatment in both media, suggest-
ing that the fermentation of glucose is not a determinant of 
SERM sensitivity in this model.
In contrast, adaptation to galactose resulted in 
decreased sensitivity to doxorubicin. Parental MCF-7 
and MCF-7-GAL cells were treated with doxorubicin for 
2 days, after which cell mass was measured by SRB stain-
ing. Galactose adapted cells had a smaller decrease in cell 




























































































Fig. 3 Tamoxifen resistant breast cancer cells have increased PDK4 mRNA expression. a cDNA prepared from cells treated identically to the cells 
used for the qCR arrays was used as template to measure expression of PDK4 mRNA and 18 s rRNA. Each reaction was performed in triplicate, and 
the average number of copies of PDK4 mRNA (upper panel) and 18s rRNA (lower panel) are shown; error bars indicate one standard deviation (n = 3 
instrument replicates). b Triplicate cultures of MCF-7L and TamR-MCF-7 cells were treated with 1 nM mifepristone, 1 nM dexamethasone, or vehicle 
control (EtOH) for 2 days in serum free media. Total RNA was extracted, and PDK4 and actin expression were measured by qPCR. The average ratio of 
PDK4 and actin are shown; error bars indicate one standard deviation (n = 3 biological replicates). Statistically difference between the average ratios 
are indicated by different letters below the chart. c PDK4 and actin mRNA were measured by qPCR in triplicate cultures of LCC-MCF-7 and LCC9 cells 
cultured and treated as described in (b)
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Because drug resistant TamR-MCF-7 cells had 
increased PDK4 mRNA but not PDK4 protein, we next 
compared the activity of PDK4′s regulatory target, 
PDH. MCF-7L and TamR-MCF-7 cells were cultured in 
growth media, and lysates were prepared and subjected 
to an in vitro PDH activity assay that measured the rate 
of NADH generation. Cultures were prepared such that 
identical independent lysates could be prepared and the 
PDH assay conducted using fresh lysates on three con-
secutive days. Despite having greater expression of PDK4 
mRNA, TamR-MCF-7 cells consistently had significantly 
elevated PDH activity compared to parental MCF-7L cells 
(Fig.  5; Additional file  1: Figure S2), suggesting TamR-
MCF-7 cells have a greater capacity to oxidize glucose.
Because TamR-MCF-7 cells had, paradoxically, ele-
vated PDK4 mRNA expression and elevated PDH activ-
ity relative to their parental cells, we wondered if the 
TamR cells expressed an altered form of PDK4. The Cata-
logue of Somatic Mutations In Cancer (COSMIC) data-
base (Forbes et al. 2008, 2015) reports that MCF-7 cells 
are heterozygous for a point mutation that results in a 
non-conservative alanine to threonine substitution at 
amino acid position 144. This position is in alpha helix 
#7, near the PDK4 catalytic site (Wynn et al. 2008). We 
designed sequencing primers around this site (Table  2) 
and sequenced the region using cDNA and genomic 
DNA as template. We confirmed the heterozygous gen-
otype reported in the COSMIC database in MCF-7L 
cells (Additional file 1: Figure S3). We found that TamR-
MCF-7 cells had loss of heterozygosity at this position; 
surprisingly TamR-MCF-7 were homozygous for the wild 
type PDK4 sequence.
To test the functional significance of PDK4 expres-
sion on antiestrogen sensitivity, we used silencing RNA 
(siRNA) to knock down PDK4 expression in TamR-
MCF-7 cells. To validate the efficacy of the siRNA, 
TamR-MCF-7 cells were transfected with PDK4 or con-
trol siRNA, then treated with dexamethasone or vehicle 
control in media containing 5 % FBS. RNA was isolated 
and reverse transcribed to cDNA, and the products used 
as template for qPCR amplification of PDK4 and actin 
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Fig. 4 Adaptation to glucose deprivation increases resistance to doxorubicin without altering antiestrogen sensitivity. ATCC-MCF-7 cells were 
adapted to growth in glucose restricted media to generate MCF-7-GAL cells. a MCF-7-GAL and galactose naïve parental cells were treated with 
1 nM ICI or control in media containing 4.5 mM glucose or 4.5 mM galactose. After 2 days, cell cycle phase distribution was determined by propid-
ium iodide staining and flow cytometry. The average percent of cells in G1 phase (light gray), S phase (white) and G2/M phase (dark gray) are shown; 
error bars indicate one standard deviation (n = 3). b MCF-7-GAL and galactose naïve parental cells were treated with the indicated concentrations 
of doxorubicin for 24 h in media containing either 4.5 mM glucose or 4.5 mM galactose. Cellular mass was measured via sulforhodamine B (SRB) 
assay. The average SRB staining is shown relative to untreated cells; error bars indicate one standard deviation (n = 6)

























Fig. 5 Tamoxifen resistant breast cancer cells have increased 
pyruvate dehydrogenase activity. On three consecutive days, lysates 
were prepared from identically treated MCF-7L and TamR-MCF-7 cells. 
Equal amounts of protein were subjected to a pyruvate dehydroge-
nase (PDH) assay. The average PDH activity expressed as NADH pro-
duced per minute per microgram of protein is shown for each assay 
replicate; error bars indicate one standard deviation (n = 3 biological 
replicates × 3 instrument replicates). The p value shown is from a two 
sided unpaired Student t test
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resulted in a smaller increase in PDK4 expression com-
pared to treatment in serum free media (Fig. 2c).
TamR-MCF-7 cells were then transfected with PDK4 or 
control siRNA and treated with 1 or 5 nM ICI for 4 days, 
after which cellular abundance was measured by SRB 
staining. A small but reproducible and statistically signif-
icant increase in ICI sensitivity was observed with PDK4 
siRNA relative to control siRNA at the highest 5 nm dose 
(Figs.  6b), suggesting PDK4 expression can mediate the 
responsiveness to SERMs. This observation was repro-
duced using a second siRNA targeting a different region 
of the PDK4 mRNA 3′ untranslated region (Additional 
file 1: Figure S4).
Discussion
The data presented above point to altered regulation of 
pyruvate dehydrogenase as mediating breast cancer cell 
sensitivity to estrogen receptor ligands such as tamoxifen 
and ICI, and reveal an important role for the serine threo-
nine kinase PDK4 in acquired SERM resistance. PDK4 is 
reported to phosphorylate and inhibit PDH, preventing 
the oxidation of carbon derived from glucose. When PDH 
is inactive, cells generate ATP through glycolysis, oxidation 
of amino acids and/or fatty acid oxidation. Rapidly divid-
ing cells such as cancer cells require not only ATP but also 
carbon for biosynthesis, and the inhibition of PDH may 
allow glucose derived carbon to be conserved for biosyn-
thesis of ribose sugars, amino acids, and glycerol, and the 
reduction of NADP+ to NADPH. We show that sensitiv-
ity to SERMs is not affected by replacing glucose with 
galactose, a non-fermentable substrate. In contrast, galac-
tose adapted cells showed resistance to the chemotherapy 
agent doxorubicin; this phenomenon has been reported 
previously in liver cancer cells (Marroquin et al. 2007).
PDK4 expression is transcriptionally regulated by 
numerous promoter elements, and its elevated mRNA 
in TamR-MCF-7 cells could indicate disruption of sev-
eral signal transduction pathways. In a glioblastoma, Kim 
et  al. describe PDK4 regulation through NF-κB activa-
tion of PGC1α (Kim et al. 2015), and NF-κB signaling is 
altered in the LCC9 model of acquired SERM resistance 
(Riggins et al. 2005). Hypoxic signaling through estrogen 
related receptor gamma (ERRγ) also activates PDK4 tran-
scription (Lee et  al. 2012; Zhang et al. 2006), and ERRγ 
is directly inhibited by 4-hydroxytamoxifen, the most 
biologically potent tamoxifen metabolite (Coward et  al. 
2001; Tremblay et  al. 2001). Knutson et  al. report that 
PDK4 expression is dependent on progesterone recep-
tor sumoylation in MCF-7 cells (Knutson et al. 2012), and 
progesterone receptor regulates breast cancer cell prolif-
eration (Skildum et al. 2005). Mifepristone is an antago-
nist of both glucocorticoid receptors and progesterone 
receptors (Beck et  al. 1993), though we did not observe 
statistically significant regulation of PDK4 mRNA 
by mifepristone in either MCF-7L or TamR-MCF-7 
(Fig.  2b). Interestingly, TamR-MCF-7 express reduced 
progesterone receptor mRNA relative to their parental 
cells (Fagan et al. 2012).
PDK4 was first identified in a linkage study of loci asso-
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Fig. 6 Reducing PDK4 expression partially restores sensitivity to antiestrogen in tamoxifen resistant breast cancer cells. a TamR-MCF-7 cells were 
transfected with siRNA targeted to PDK4 or a non-specific control siRNA. The next day, they were treated with 1 nm dexamethasone in media con-
taining fetal bovine serum. Two days later, total RNA was collected, and PDK4 and β-actin mRNA expression was measured by qPCR as described. 
The average ratio of PDK4 mRNA to b-actin mRNA is shown; error bars indicate one standard deviation (n = 3 biological replicates). b MCF-7L and 
TamR-MCF-7 cells were transfected with PDK4 or control siRNA. The next day, cells were treated with the indicated doses of ICI or vehicle control. 
After 4 days, cellular mass was measured by sulforhodamine B staining. The average SRB staining is shown relative to vehicle treated samples; error 
bars indicate one standard deviation (n = 4). Different letters indicate statistically significant differences determined by ANOVA and Tukey–Kramer 
honest significant differences comparisons
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(Rowles et  al. 1996), and insulin is known to repress 
PDK4 transcription (Wu et  al. 1998; Majer et  al. 1998). 
Interestingly, in serum free media we show that the 
regulation of PDK4 by the glucocorticoid receptor ago-
nist dexamethasone only occurs in drug resistant breast 
cancer cells (Fig.  2c), while the dexamethasone induc-
tion is dramatically blunted when TamR-MCF-7 cells 
are treated in the presence of fetal bovine serum (Fig. 7a; 
Additional file 1: Figure S4a). Insulin inhibits glucocorti-
coid dependent expression of PDK4 expression by pre-
venting FOXO1 translocation to the nucleus (Kwon et al. 
2004). Together these results suggest that in the absence 
of insulin and other growth factors in serum, parental 
MCF-7 cells have increased FOXO1 activity compared 
to TamR-MCF-7 cells, but that serum growth factors are 
still capable of blunting PDK4 expression by dexametha-
sone in these cells.
The consequences of PDK4 expression on cancer pro-
gression and response to therapy are likely to be context 
dependent. PDK4 was shown to be abundant in patient 
glioblastoma compared to normal tissue, and indirectly 
reducing its expression through shRNA targeting the 
RelA subunit of NF-kB resulted in reduced growth of 
xenografts in nude mice (Kim et  al. 2015). Similarly, 
reducing PDK4 directly through shRNA resulted in 
increased tumor free survival of mice bearing prostate 
cancer cell xenografts (Liu et  al. 2014). In contrast, in 
lung cancer cells decreasing PDK4 expression both pre-
vented the antiproliferative action of a PPARγ agonist by 
blocking its action at the G1 → S phase checkpoint (Sriv-
astava et al. 2014) and promoted epithelial to mesenchy-
mal transition and chemotherapy resistance. The latter 
effects may be due to PDK4 physically interacting with 
the mitochondrial apoptosis inducing factor (AIF) rather 
than its phosphorylation of PDH (Sun et al. 2014; Cande 
et al. 2002).
Although PDK4 mRNA is overexpressed in TamR-
MCF-7 cells relative to their tamoxifen naïve parental 
cells, PDK4 protein levels are similar and PDH activity is 
higher in TamR-MCF-7. These results suggest that PDK4 
in TamR-MCF-7 is not acting as an inhibitor of PDH. 
Increased mRNA without increased protein level is con-
sistent with decreased translation and/or increased pro-
tein turnover. If PDK4 protein turnover is increased in 
TamR-MCF-7 cells, the increased PDH activity in these 
cells may be result because PDK4 does not have time to 
be appropriately post-translationally modified or trans-
ported to the mitochondria. PDK4 has several sites iden-
tified as phosphorylated in proteomic screens (Franchin 
et al. 2015; Hornbeck et al. 2012), but the significance of 
these modifications with respect to PDK4 or PDH activ-
ity have not been characterized. Newly synthesized PDK4 
may have reduced PDH inhibitory activity, and/or may 
act through targets other than PDH (e.g. AIF). These pos-
sibilities, and the significance of PDK4 polymorphisms, 
are currently under study.
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Additional file 1: Figure S1. Volcano plot showing glucose metabolism 
genes differently expressed in TamR-MCF-7 and parental MCF-7L. Expres-
sion of glucose metabolism genes were compared using qPCR arrays. 
Genes expressed higher in TamR-MCF-7 cells are represented by dots on 
the right side of the plot while genes expressed at lower levels in TamR-
MCF-7 are on the left side. qPCR arrays were performed on separately 
prepared triplicate cultures; the vertical axis shows the p value for each 
gene. The dots representing phosphoglucomutase (PGM), glucokinase 
(GCK) and pyruvate dehydrogenase kinase -4 (PDK4) are indicated by gray 
circles. Figure S2. TamR-MCF-7 cells have increased pyruvate dehydroge-
nase activity relative to parental MCF-7L cells. On three consecutive days, 
lysates were prepared from identically treated MCF-7L and TamR-MCF-7 
cells. Equal amounts of protein from each cell line were subjected to a 
pyruvate dehydrogenase (PDH) assay. The average PDH activity expressed 
as NADH produced per minute per microgram of protein is shown for 
each assay replicate; error bars indicate one standard deviation (n = 3 
instrument replicates). Asterisks indicate significantly different (p < 0.05) 
averages as determined by unpaired two tailed Student’s T tests. The num-
bers below each day indicate the amount of protein loaded in each assay. 
Figure S3. Tamoxifen resistant breast cancer cells have loss of heterozy-
gosity at amino acid position 144 in the PDK4 protein. MCF-7L cDNA and 
genomic DNA was used as template for sequencing of the DNA around 
base position 430 of PDK4 mRNA. Forward and reverse reads are shown; 
wild type and mutant sequences are shown below. Figure S4. Reducing 
PDK4 expression partially restores sensitivity to antiestrogen in tamoxifen 
resistant breast cancer cells. A) TamR-MCF-7 cells were transfected with an 
siRNA targeting a different region of the PDK4 mRNA than that shown in 
Fig. 6 or a non-specific control siRNA. The next day, they were treated with 
1nm dexamethasone in media containing fetal bovine serum. Two days 
later, total RNA was collected, and PDK4 and β-actin mRNA expression 
was measured by qPCR as described. The average ratio of PDK4 mRNA to 
b-actin mRNA is shown; error bars indicate one standard deviation (n = 3 
biological replicates). B) MCF-7L and TamR-MCF-7 cells were transfected 
with the PDK4 siRNA used in Figure S4A or control siRNA. The next day, 
cells were treated with the indicated doses of ICI or vehicle control. After 
four days, cellular mass was measured by sulforhodamine B staining. The 
average SRB staining is shown relative to vehicle treated samples; error 
bars indicate one standard deviation (n = 4). Different letters indicate sta-
tistically significant differences determined by ANOVA and Tukey-Kramer 
Honest Significant Differences comparisons.
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